• 1

    Germline testing: who should be tested, how and for what?

  • 2

    How can we integrate the complex and multidisciplinary management of germline BRCA-associated BC?

  • 3

    Do DNA repair mutations beyond germline BRCA matters for patient’s management?


Summary of the Multidisciplinary management of germline and somatic gene alterations in patients with metastatic breast cancer

  • BRCA1/2 germline testing is moving to mainstream oncology care in breast cancer patients
  • BRCA1/2 germline testing in cancer patients allows cascade testing in relatives at risk to tailor early detection/prevention recommendations
  • A multidisciplinary approach is needed to face the multiple implications of germline testing including variants interpretation, cost, and public health policy for cancer prevention
  • Management of advanced BRCA1/2 BC patients includes option of targeted therapies and consideration of PBSO (therapeutic and/or preventive)
  • PALB2 mutations associated with high BC risk and HRD 🡪 PARPi and platinum
  • ATM and CHEK2 BC are ER+/HER2- and lack features of HRD

This event is sponsored by: :



Judith Balmaña MD PhD

Medical Oncology, University Hospital Vall d’ ...

Barcelona, Spain

ESMO Faculty Coordinator of the Cancer Genetics Group, Dr Balmaña is author of many peer-reviewed articles and book chapter in her fields of expertise

Comments (0)